INCB191358

INCB191358: sourced facts only. name: "Structure-activity relationship studies demonstrated that incorporation of a 4-phenoxypiperidine improved pharmacokinetic properties and culminated in the discovery of INCB191358 (52), a potent, selective, and orally bioavailable dual DGKα/ζ inhibitor." [PMID:41996127]; target: "Structure-activity relationship studies demonstrated that incorporation of a 4-phenoxypiperidine improved pharmacokinetic properties and culminated in the discovery of INCB191358 (52), a potent, selective, and orally bioavailable dual DGKα/ζ inhibitor." [PMID:41996127]; developer: "Incyte Research Institute, Incyte Corporation, 1801 Augustine Cut-Off, Wilmington, Delaware 19803, United States." [PMID:41996127]; stage: "In vivo, 52 achieved transient, yet highly efficacious target coverage, inducing antigen-dependent T-cell activation in a mouse pharmacodynamic model and enhancing antitumor efficacy in a syngeneic tumor model when combined with PD-1 blockade." [PMID:41996127]